Spots Global Cancer Trial Database for A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate the Safety and Efficacy of Nivolumab With Ipilimumab in Participants With Untreated Advanced Kidney Cancer Conducted in India
Official Title: A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India
Study ID: NCT04513522
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the safety and efficacy of nivolumab combined with ipilimumab in intermediate and poor-risk participants with previously untreated advanced renal cell carcinoma (RCC) or metastatic RCC (mRCC) in India.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: Yes
Locations
Local Institution - 0007, New Delhi, Delhi, India
Local Institution - 0005, Ahmedabad, Gujarat, India
Local Institution - 0011, Trivandrum, Kerala, India
Local Institution - 0001, Mumbai, Maharashtra, India
Local Institution - 0006, Bangalore, , India
Local Institution - 0017, Delhi, , India
Local Institution - 0002, Karnataka, , India
Local Institution - 0019, Kolkata, , India
Local Institution - 0016, Mumbai, , India
Local Institution - 0013, Mumbai, , India
Local Institution - 0012, Pune, , India
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
